The global lung stent market involves insertion of small tubes known as stents into air passages of the lungs to keep them open for patients suffering from lung cancer or other lung diseases. Stents are used to treat conditions like tracheobronchomalacia and bronchostenosis that cause narrowing or collapse of airways. Made of metal or silicon materials, lung stents improve breathing by widening the airway and preventing further blockage. The demand for lung stents is rising due to increasing incidence of lung cancer, chronic obstructive pulmonary disease (COPD) and other respiratory disorders.

 The Global Lung Stent Market is estimated to be valued at US$ 206.5 million in 2024 and is expected to exhibit a CAGR of 7.1% over the forecast period of 2024 to 2031.

Key Takeaways

Key players operating in the global lung stent market are Boston Scientific, Cook Medical, Medtronic, Taewoong Medical, Hospitech, Bess, Endo-Flex, Efer Endoscopy, W. L. Gore & Associates, BD, Edwards Lifesciences, Healthy Medical Corporation, Pulmonx Corporation, Meril Life Sciences Pvt. Ltd and C. R. Bard Inc. Key players are focusing on developing customized lung stents to treat complex airway abnormalities. For instance, Boston Scientific offers customized Nitinol stents like Esophageal Stents and Tracheobronchial Stents.

The growing demand for minimally invasive procedures and rising lung cancer incidence globally is propelling the  Global Lung Stent Market Growth. According to the National Cancer Institute, lung cancer is the second most common cancer in the world, with over 2.1 million new cases reported annually. Expanding aging population vulnerable to chronic respiratory diseases is another factor fueling the demand.

Geographic expansion into emerging nations is another key strategy adopted by leading players. Latin American and Asia Pacific markets offer high growth potential owing to improving healthcare access and increasing disposable incomes in these regions.

Market Key Trends
Customized stents are gaining prominence to treat complex lung conditions. 3D printing and computer-aided designs are enabling manufacturers to produce patient-specific stents tailored as per the size and contours of individual airways. This significantly improves treatment efficacy and outcome. Pulmonx Corporation is a leader in designing customized Zephyr valves using 3D printing for severe emphysema. Going forward, advanced technologies will facilitate production of highly customized stents on a large scale to address unmet needs in the lung stent market.

Explore More Articles – Commercial Display Market